REVB Stock ,Revelation Biosciences, Inc. is a biopharmaceutical company in the clinical stage. The company is focused on creating and commercializing immunelogic therapies and diagnostics. Its therapeutic products are built upon its therapeutic platform. They consist of REVTx-100. It is being developed to aid in the treatment or prevention of infections, such as ones resulting from surgical procedures, severe burns, and resistance to antibiotics; REVTx-200 which is being developed for intranasal treatment that is intended on administering an available intramuscular (IM) vaccine as well as REVTx-300 that is being developed as an option for treating chronic organ diseases that includes CKD as well as NASH. REVTx-99b that is being developed for treating food allergy. The diagnostic developed by the Company, REVDX-501 (REVIDTM Quick Test Kit), is being developed as a fast point of care or home diagnostic device that could possibly be used to identify numerous viruses that cause respiratory infections.
Revelation Biosciences Inc. Announces Pricing
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company in the clinical stage which is focused to develop immunologic treatments for the prevention and treatment of diseases it has announced today the price of an open public offering consisting of 325,000 common shares (or equivalents to common stock) along with warrants for the purchase of up to 6,450,000 shares in its stock at an offer price for that of the general public at $4.83 per share, as well as a warrants. The warrants will be issued at an exercise cost that is $5.36 per share. They will be convertible upon issuance and expire 5 years after the date of the issuance. The close of the offering is anticipated to take place around February 13th 2023, subject to the fulfillment of standard closing conditions.
Revelation Biosciences Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| REVB | -96.85% | -99% | ||
| S&P | -8.93% | +57.20% | +9.47% | +13% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $6.20M | – |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.00M | – |
| Short Term Debt | $0.00M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -27.1% | +311.5% |
| Return On Invested Capital | 30.8% | -37.0% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$1.73M | +514.0% |
| Operating Free Cash Flow | -$1.73M | +514.0% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | 37.56 | – |
| Price to Book | 1.67 | -174.54 | -9.08 | 2.76 | +101.2% |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 48.54 | 5.43 | -5,948.23 | -74.76 | – |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -91.88 | -1.37 | -7.15 | 0.59 | – |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -4.0% | -28.8% | -31.7% | -31.4% | +314.4% |
| Total Debt | $0.77M | $0.00M | $0.00M | $0.00M |
